Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Zkoumání neurobiologických mechanismů, které jsou základem terapeutického účinku ketogenní diety u bipolární poruchy (BD)

9. listopadu 2026 aktualizováno: Mary Phillips, MD MD (Cantab), University of Pittsburgh

Objasnění neurobiologických mechanismů, které jsou základem terapeutického účinku ketogenní stravy u bipolární poruchy (BD): multidisciplinární mechanická studie

The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).

Přehled studie

Detailní popis

The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.

Typ studie

Intervenční

Zápis (Odhadovaný)

107

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • Nábor
        • University of Pittsburgh Medical Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Mary L Phillps, MD, MD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 40 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

All participants:

  • 18-40 years of age
  • Not following a ketogenic diet

BD hypomanic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) (Diagnostic and Statistical Manual of Mental Disorders 5; DSM-5)
  • Score greater than 10 on the Young Mania Rating Scale score(YMRS)
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
  • Score less than or equal to 10 on YMRS
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group (n=30):

  • Sex matched with BD groups
  • No psychiatric history

Exclusion Criteria:

All participants:

  • Not between 18-40 years of age
  • History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
  • Mini-Mental State Examination score (cognitive state) <24
  • Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate<85
  • Visual disturbance: <20/40 Snellen visual acuity
  • History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
  • MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
  • Unable to understand English
  • Conditions related to the pancreas, liver, thyroid or gallbladder.
  • Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
  • Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
  • Currently following a ketogenic diet
  • Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)
  • Taken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month

BD hypomanic group:

  • Must be meeting sex proportions: not 50% female
  • Must be meeting diagnosis proportions: not 50:50% BDI:II (DSM-5)
  • Diagnosis of BD in a manic or euthymic episode
  • Score 10 or lower on the Young Mania Rating Scale score(YMRS)
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group:

  • Not meeting sex proportion: not 50% female
  • Not meeting diagnosis proportion: not 50:50% BDI:II
  • Diagnosis of BD in a depressive, hypomanic, or manic episode
  • Score greater than 10 on YMRS
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group

  • Not sex-matched with BD groups
  • Has psychiatric history

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Randomizované
  • Intervenční model: Crossover Assignment
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: 1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet

Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study

Consuming a non-ketogenic diet

Consuming a ketogenic diet

Experimentální: 1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet

Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study

Consuming a non-ketogenic diet

Consuming a ketogenic diet

Jiný: No diet

Participants without Bipolar Disorder will not participate in the diet phases of the study

Participants without Bipolar Disorder will not participate in the diet phases of the study

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Blood oxygen level-dependent (BOLD) signal at Scan 1
Časové okno: Baseline Scan 1 (all participants)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

Baseline Scan 1 (all participants)
Blood oxygen level-dependent (BOLD) signal at Scan 2
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Blood oxygen level-dependent (BOLD) signal at Scan 3
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 1
Časové okno: Baseline Scan 1 (all participants)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Baseline Scan 1 (all participants)
Manic symptoms at Scan 2
Časové okno: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 3
Časové okno: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at Baseline
Časové okno: Baseline (all participants)

Fasting glucose blood levels

Baseline (all participants)
Fasting lipids at Baseline
Časové okno: Baseline (all participants)

Fasting lipid blood levels

Baseline (all participants)
Fasting hepatic function panel at Baseline: total protein
Časové okno: Baseline (all participants)

Fasting levels of total protein in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: albumin
Časové okno: Baseline (all participants)

Fasting levels of albumin in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: bilirubin
Časové okno: Baseline (all participants)

Fasting levels of bilirubin in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: liver enzyme
Časové okno: Baseline (all participants)

Fasting levels of liver enzyme in the blood

Baseline (all participants)
Fasting Glucose at halfway point through first dietary phase
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through first dietary phase
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: total protein
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: albumin
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: bilirubin
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: liver enzyme
Časové okno: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of first dietary phase
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of first dietary phase
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: total protein
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: albumin
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: bilirubin
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: liver enzyme
Časové okno: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at halfway point through second dietary phase
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through second dietary phase
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: total protein
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: albumin
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: bilirubin
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: liver enzyme
Časové okno: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of second dietary phase
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of second dietary phase
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting lipids blood levels

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: total protein
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: albumin
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: bilirubin
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: liver enzyme
Časové okno: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at Baseline
Časové okno: Baseline Scan 1 (all participants)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Baseline Scan 1 (all participants)
Glutamate at Baseline
Časové okno: Baseline Scan 1 (all participants)

Glutamate concentrations in the brain

Baseline Scan 1 (all participants)
Lactate at Baseline
Časové okno: Baseline Scan 1 (all participants)

Lactate concentrations in the brain

Baseline Scan 1 (all participants)
Gamma-aminobutyric acid (GABA) at end of first dietary phase
Časové okno: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of first dietary phase
Časové okno: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Glutamate concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of first dietary phase
Časové okno: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Lactate concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at end of second dietary phase
Časové okno: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of second dietary phase
Časové okno: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Glutamate concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of second dietary phase
Časové okno: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Lactate concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Average total sleep time during Ketogenic vs Normal diet
Časové okno: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals

Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.

Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet
Časové okno: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.

Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home

Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring
Časové okno: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring
Časové okno: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring
Časové okno: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring
Časové okno: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring
Časové okno: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring
Časové okno: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Mary Phillips, MD, University of Pittsburgh

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

12. ledna 2024

Primární dokončení (Odhadovaný)

1. června 2027

Dokončení studie (Odhadovaný)

1. června 2027

Termíny zápisu do studia

První předloženo

22. září 2023

První předloženo, které splnilo kritéria kontroly kvality

5. října 2023

První zveřejněno (Aktuální)

13. října 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).

Časový rámec sdílení IPD

The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.

Kritéria přístupu pro sdílení IPD

Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit